Phase IB Intravesical Administration of SCH 721015

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01162785
First received: July 13, 2010
Last updated: October 14, 2013
Last verified: October 2013
  Purpose

The goal of this part (Part 1) of this clinical research study is to learn about the safety of giving 2 doses of SCH 72105 (also known as rAd-IFN) directly into the bladder to patients with bladder cancer that has come back. The goal of Part 2 of this study is to learn about the safety of giving 2 more doses of SCH 72105 directly into the bladder of Part 1 participants who had no sign of bladder cancer after Week 12. The level of effectiveness of SCH 72105 will also be studied by measuring the interferon (IFN) levels in the urine.


Condition Intervention Phase
Bladder Cancer
Drug: SCH 721015
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer

Resource links provided by NLM:


Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Safety + Tolerability of 2 Instillations of Intravesical SCH 721015 in Admixture with Novel Excipient SCH 209702 (Syn3) on Day 1 and Day 4 [ Time Frame: Daily urine collection for 14 days ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 9
Study Start Date: April 2011
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: First Dose SCH 721015
Part1: 2 Instillations of intravesical SCH 721015 (on Day 1 and 4) at a dose concentration of 3x1011particles/mL given in a 75 mL total volume
Drug: SCH 721015
Intravesical SCH 721015 (on Day 1 and 4) at a dose concentration of 3x1011particles/mL given in a 75 mL total volume. Administered into bladder through a urinary catheter, 75 mL will be instilled, left in the bladder for 1 hour, plus or minus 10 minutes. During the dwell time, subject will be repositioned from left to right, back and abdomen to maximize bladder surface exposure, approximately every 15 minutes.
Other Name: rAd-IFN
Experimental: Second Dose SCH 721015
Part 2: Subjects who have a complete response to treatment at Week 12 in Part 1 receive second regimen of intravesical administration of SCH 721015 with Syn3 on same Day 1 and Day 4 regimen at same dose level.
Drug: SCH 721015
Intravesical SCH 721015 (on Day 1 and 4) at a dose concentration of 3x1011particles/mL given in a 75 mL total volume. Administered into bladder through a urinary catheter, 75 mL will be instilled, left in the bladder for 1 hour, plus or minus 10 minutes. During the dwell time, subject will be repositioned from left to right, back and abdomen to maximize bladder surface exposure, approximately every 15 minutes.
Other Name: rAd-IFN

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects must be willing to give written informed consent and be able to adhere to dose and visit schedules.
  2. Histologically proven recurrent urothelial carcinoma of the bladder or prostatic urethra, Stage Tis, Ta
  3. Patients with recurrent T1 disease who do not wish to have cystectomy.
  4. Subjects must have failed at least two prior courses of BCG with or without recombinant interferon alpha administration or be BCG intolerant. This includes either two six week induction courses of BCG or a 6 week induction course followed by a 3 week mini-induction course of maintenance BCG.
  5. At least 3 months must have passed since last BCG therapy or intravesical treatment for bladder carcinoma.
  6. Subjects must be 18 years of age or older
  7. Life expectancy of at least 3 months
  8. Adequate performance status (Karnofsky score >/= 70%)
  9. Adequate laboratory values. a) Hemoglobin >/=10 gm/dL. b) WBC >/= 3000/µL. c) ANC >/= 1500/µL. d) Platelet count >/=100,000/µL. e) PT </= 1.5 x ULN. f) aPTT </= 1.5 x ULN. g) AST </=1.5 x ULN. h) ALT </= 1.5 x ULN. i) Total bilirubin </= 1.5 x ULN. j) Creatinine </=1.5 x ULN.
  10. Female subjects of childbearing potential (Female subjects who are not surgically sterilized, not at least 1 year postmenopausal) must agree to use adequate contraception (e.g. IUD, condom plus spermicide, diaphragm, or cervical cap plus spermicide) or medical contraception: during the study and for at least 1 month prior to drug administration and for 4 months after treatment. Females who are not currently sexually active must agree and consent to use one of the above-mentioned methods should they become sexually active while participating in the Study.
  11. Male subjects who are sexually active must agree to use a condom from the beginning of treatment and for 1 month after the last dose

Exclusion Criteria:

  1. Pregnant or nursing women
  2. Suspected hypersensitivity to interferon alpha
  3. Participation in another clinical trial or use of any investigational drug within 30 days prior to study entry
  4. Subjects with organ transplants
  5. Any known preexisting medical condition that could interfere with the subject's participation in and completion of the study such as:
  6. b. CNS trauma or active seizure disorders requiring medication
  7. c. Significant cardiovascular dysfunction within the past 6 months including symptomatic cardiac ischemia, arrhythmia or congestive heart failure requiring hospitalization or emergency room visit within last 3 months
  8. d. Poorly controlled diabetes mellitus (HbA1C >10.0%);
  9. e. Unstable pulmonary disease requiring hospitalization or emergency room visit within the last 3 months.
  10. f. Immunologically mediated disease (eg, rheumatoid arthritis, autoimmune hepatitis, immune mediated glomerulonephritis).
  11. Donation of blood within the preceding 60 days prior to study registration.
  12. Any other condition that, in the opinion of the investigator, would make the subject unsuitable for enrollment or could interfere with the subject participating in and completing the protocol.
  13. History of any clinically significant local or systemic infectious disease within 4 weeks prior to initial treatment administration
  14. Untreated bladder infection
  15. Positive for hepatitis BsAg or HIV Ab or hepatitis C
  16. Immunosuppressive therapy within the last 3 months
  17. Subjects who are part of the staff personnel directly involved with this study
  18. Subjects who are family members of the investigational study staff
  19. Traumatic catheterization within 1 month
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01162785

Locations
United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Merck Sharp & Dohme Corp.
Investigators
Study Chair: Colin P. Dinney, MD UT MD Anderson Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT01162785     History of Changes
Other Study ID Numbers: 2009-0938, P50 CA91846
Study First Received: July 13, 2010
Last Updated: October 14, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by M.D. Anderson Cancer Center:
BCG Refractory Superficial Bladder Cancer
SCH 721015
Syn3
novel excipient
interferon -alpha-2b
Intravesical
urine IFNa
transitional cell carcinoma of the bladder
superficial non-muscle invasive tumor

Additional relevant MeSH terms:
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on September 18, 2014